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Abstract 
Background: Worldwide demand for SARS-CoV-2 RT-PCR testing is increasing as more countries are 
impacted by COVID-19 and as testing remains central to contain the spread of the disease, both in 
countries where the disease is emerging and in countries that are past the first wave but exposed to 
re-emergence. Group testing has been proposed as a solution to expand testing capabilities but 
sensitivity concerns have limited its impact on the management of the pandemic. Digital PCR (RT-dPCR) 
has been shown to be more sensitive than RT-PCR and could help in this context. 
 
Methods: We implemented RT-dPCR based COVID-19 group testing on commercially available system 
and assay (Naica™ System from Stilla Technologies) and investigated the sensitivity of the method in 
real life conditions of a university hospital in Paris, France, in May 2020. We tested the protocol in a 
direct comparison with reference RT-PCR testing on 448 samples split into groups of 3 sizes for RT-
dPCR analysis: 56 groups of 8 samples, 28 groups of 16 samples and 14 groups of 32 samples. 
 
Results: Individual RT-PCR testing identified 25 positive samples. Using groups of 8, testing by RT-dPCR 
identified 23 groups as positive, corresponding to 26 true positive samples including 2 samples not 
initially detected by individual RT-PCR but confirmed positive by further RT-PCR and RT-dPCR 
investigation. For groups of 16, 15 groups tested positive, corresponding to 25 true positive samples 
identified. 100% concordance is found for groups of 32 but with limited data points. 
 
Conclusions: Our proposed approach of group testing by digital PCR is shown to have a similar to better 
diagnostic sensitivity compared to individual RT-PCR testing for group sizes of up to 16 samples. This 
approach reduces the quantity of reagent needed by up to 80% while reducing costs and increasing 
capabilities of testing by up to 10-fold. 
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Introduction 
As the first wave of the COVID-19 is fading in most countries of the Northern hemisphere, many of 
them have started implementing extensive monitoring policies to prevent the apparition of new 
clusters potentially leading to a second wave. These policies all require important testing capabilities, 
as was exemplified in Wuhan where all 11 Million citizens were recently tested in 10 days during May 
2020. In some Southern countries, the amount of new cases is still increasing and wide population 
testing cannot be achieve everywhere. Thus, scaling up and maintaining large testing capacities 
worldwide remains a challenge, with limited reagent production and scarcity of testing equipment 
likely to remain limitations.  
 
Group testing or pooling, first suggested by Dorfman in 1943, is a protocol through which individual 
samples are combined together before running the test(1). The advantage of the method is an overall 
saving in the number of tests required to screen a given population (2), and thereby an increase in 
testing capabilities for fixed reagent and instrumentation availability. Savings depend on key 
parameters such as the disease prevalence and the group size.  Group testing protocols using real-time 
reverse-transcriptase PCR (RT-PCR) have been evaluated and implemented for Covid-19 screening 
around the world in several experiments using RT-PCR detection techniques, notably in Israel, 
Germany, California, Nebraska, NY State, and Italy (3–9).  
 
Although these studies show that positive individuals can be detected in pooled samples, the number 
of amplification cycles needed to detect (Ct value) those is often increased by dilution and perhaps by 
inhibition effects (3,5,7,9). This can prevent weakly positive specimen from being detected in group 
samples (3,8). Concerns about the sensitivity of group testing have been raised by French medical 
authorities, leading to a negative recommendation on their use in France(10). 
 
Digital PCR (or RT-dPCR) is a PCR technique known for its higher sensitivity and precision over classical 
RT-PCR (11,12). Digital PCR has also been shown to be more resistant to PCR inhibitors (13). Recent 
studies have confirmed high sensitivity of RT-dPCR for the detection of SARS-CoV-2 (14–16). 
In this study we propose a novel group testing protocol using a commercially available RT-dPCR assay 
and compare empirically the sensitivity of individual identification through RT-PCR with group testing 
by RT-dPCR for three groups sizes of 8, 16 and 32 samples. We find that, in our condition of evaluation, 
group testing by RT-dPCR has a better or similar sensitivity than the reference individual RT-PCR testing 
for groups of 8 and 16.  
Material and Methods 
Summary of the method of the comparative study 
Overall, 448 patient samples are tested for SARS-CoV-2 by i) individual RT-PCR (local gold standard 
method), ii) RT-dPCR in 56 groups of 8 samples, iii) RT-dPCR in 28 groups of 16 samples and iv) RT-dPCR 
in 14 groups of 32 samples and results are compared between all four test protocols. In case of 
discordance between the results of individual RT-PCR testing and group testing in RT-dPCR, samples 
were re-analyzed individually by RT-dPCR, by the gold-standard RT-PCR and a confirmatory RT-PCR 
assay. The whole protocol is illustrated in Figure 1. 
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Figure 1 : Schematic of the structure of the comparative study. 
 
Specimens collection, storage and pooling 
Nasopharyngeal swabs of 448 patients screened for Covid-19 at the Bichat university hospital (Paris, 
France), one of the two Paris reference centers for emerging diseases, between May 6th and May 26th, 
2020 were included. All samples were collected in universal transport medium (UTM) (Virocult® or 
eSwabTM) and tested, within 15 hours maximum upon collection, for SARS-CoV-2 detection according 
to the local standards. Briefly, 400 µL of transport medium were tested by RT-PCR (Cobas SARS-CoV-2 
test, Roche). All the remaining volume of transport medium of all specimens were kept at +5°C.  
No later than 24 hours after routine screening, all samples with a leftover UTM volume above 600 µL 
were systematically included in the group testing analysis. Thus, 125 µL of each included specimen 
were sampled and randomly mixed with seven others to generate a total of 56 groups of 8 specimens 
with a final volume of 1 mL per group. Nucleic acids were extracted from each group prior to viral 
titration by RT-dPCR. The remaining volume of transport medium was stored at +5°C for further 
investigations if required. 
According to the current French ethical laws, samples used in the current study were only included 
after the completion of all analysis required for the patient’s care.  
Detection of SARS-CoV-2 by routine individual RT-PCR testing 
All 448 specimens were analyzed individually on a Cobas® 6800 system (Roche, Switzerland) for Covid-
19 screening using the Cobas® SARS-CoV-2 Test kit targeting conserved regions for ORF-1a/b and E-
gene. For each specimen, 400 µL of transport medium were mixed with 400 µL of Cobas® lysis buffer 
and loaded on the robot. During the run, extracts were eluted in 50 µL of which 27 µL were used in the 
RT-PCR amplification of E and ORF-1a/b.  A sample was considered positive for routine screening of 
COVID-19 (“RT-PCR+”) if either target had a Ct value below 40 PCR cycles. 
Within 11 days maximum (and 20 days for “Sample_25659”) upon storage at +5°C, some samples 
which had different results for RT-PCR and RT-dPCR were reassessed on the Cobas® 6800 system. To 
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compensate for the low remaining amounts of transport medium, the nasal swabs were vortexed once 
more into the remaining transport medium diluted 1 to 10 with new transport medium. 
Extraction of total NAs on grouped samples 
All nucleic acids extractions for RT-dPCR assays were performed on a MagNA Pure LC 2.0 (Roche, 
Switzerland) using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Switzerland) following 
manufacturer’s instructions. For all sample groups, the total volume of 1 mL was used for the 
extraction. For individual samples, 200 µL was diluted with 800 µL of buffer before extraction. Nucleic 
acids were eluted from 1mL to 50 µL of the elution buffer provided with the kit and stored at +5°C for 
a maximum of 12 hours before analysis. 
Preparation of groups of 16 and 32 individuals 
After extraction of the 56 groups of 8 specimen (P8 extracts) and prior to viral titration by RT-dPCR, 28 
groups of 16 individual samples (P16 groups) were obtained by mixing 15 µL of 2 P8 extracts and 14 
groups of 32 (P32 groups) were obtained by mixing 10 µL of 2 P16 groups. 
Detection of SARS-CoV-2 by grouped RT-dPCR testing 
SARS-CoV-2 titration of the grouped samples by RT-dPCR was performed on the Naica system (Stilla 
Technologies, France) within the next three hours after extraction, using the COVID-19 Multiplex 
Digital PCR Detection Kit (Stilla Technologies, France/Apexbio, China).  This one-step reverse-
transcription PCR kit is a triplex PCR allowing amplification, detection and quantification of one 
sequence in the N gene, one sequence in the ORF1ab region of SARS-CoV2 and an endogenous internal 
control (IC) to assess the quality of the sample and extraction. These sequences are targeted by three 
TaqMan probes respectively labelled with a FAM, HEX and Cy®5 fluorophore. 
As recommended by the kit manufacturer, the PCR mix for a single reaction contained 12.5 µL of dPCR 
MasterMix 1, 1 µL of dPCR Mix 2, 1 µL of COVID-19 Assay and 10.5 µL of either, P8, P16, P32, positive 
control, negative control or individual extract. The 25 µL of this PCR mix were loaded in the inlet ports 
of the Sapphire chips (Stilla Technologies, France). The chips were placed in the Naica Geode (Stilla 
Technologies, France) for droplets generation, reverse transcription and PCR amplification following 
the kit manufacturer’s instructions. 
After amplification, the chips were transferred to the Naica Prism3 (Stilla technologies, France) for 
fluorescence reading in the three detection channels and data were analyzed with Crystal Miner 
Software (Stilla Technologies, France) following the kit manufacturer’s instructions. 
An illustration of the resulting fluorescence dot-plots used to quantify the SARS-CoV-2 virus by RT-
dPCR is shown in Supplementary Materials. 
Individual confirmatory testing for SARS-CoV-2 by RT-PCR and RT-dPCR 
In case of discrepancies between individual RT-qPCR and grouped RT-dPCR, RT-dPCR results were 
confirmed by extracting individually each sample of the group and retesting them individually 
according to the previously described RT-dPCR protocol. Confirmatory RT-qPCR test were also 
performed on individual samples as previously described with the Cobas SARS-CoV-2 assay and a third 
method, RealStar® SARS CoV-2 RT-PCR Kit (Altona Diagnostics, Germany), was also performed on an 
ABI 7500 thermocycler (ThermoFisher Scientific, United-States) from the same individual extraction as 
for the confirmatory RT-dPCR assay. Briefly, this latter assay targets all lineage B-betacoronaviruses by 
amplifying a sequence of the E gene and a sequence of the S gene specific to SARS-CoV-2 as well as a 
heterologous internal control. A sample was considered positive to SARS-CoV-2 if the Ct value of either 
target is below 40 PCR cycles.  
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LoB/LoD evaluation for SARS-CoV-2 detection using RT-dPCR 
The Limit of Blank (LoB) and Limit of Detection (LoD) were evaluated for SARS-CoV-2 detection using 
the group testing approach used in the study on a cohort of 256 pre-epidemic nasal swab samples 
(negative control samples) that were collected between December 1st 2019 and January 31st 2020 and 
for which transport medium was stored at -20 °C within 48h after sampling. 
Specimens were randomly grouped into 32 groups of 8 negative controls which were co-extracted and 
analyzed by RT-dPCR using the same protocol described above. The results for all 32 groups are given 
in Supplementary Materials. The LoB at 95% confidence level for the N target and the ORF1ab target 
is determined to be of 2 and 0 positive droplets respectively. The LoD at 95% confidence level for each 
target is of 0.49 copies / µL (7 copies/PCR) and 0.24 copies/µL (3 copies/PCR), respectively. 
Consequently, a threshold of a least 3 positive droplets in aggregate between both the N target and 
ORF1ab target is used to classify a sample as positive to SARS-CoV-2 by RT-dPCR in this study.  
Results 
Cohort description from routine RT-PCR testing 
Using routine RT-PCR testing, 25 samples were identified as positive out of the 448 samples tested, 
corresponding to an average test positivity rate of 5.5%. The positivity rate decreased during the study 
period from 8.5% for the first 224 samples to 2.5% for the last 224 samples, in correlation with the 
decreasing disease prevalence observed during the month of May in France.  
The average Ct value was of 30.0 and 27.3 for the E gene and ORF gene respectively, with minimum 
values of 16.5 and 16.3 and maximum values of 38.7 and >40 (not detected) (Figure 2).  
 
 
Figure 2 : Distribution of Ct values for the E gene and ORF gene, as measured using individual reference RT-PCR with Cobas® 
6800 SARS-CoV-2 assay, for the 25 positive samples. 
Results from grouped RT-dPCR testing 
All results for the detection of SARS-CoV-2 by RT-dPCR for the grouped extracts (P8) and the 
subsequent groups of 16 (P16) and 32 (P32) are presented in Table 1. Detailed results are listed in 
Supplementary Materials. 
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Number of RT-PCR positive 
sample(s) in the group 
Results for P8 extracts Results for P16 groups Results for P32 groups 
Total dPCR - dPCR + Total dPCR - dPCR + Total dPCR - dPCR + 
0 35 32 3 12 11 1 2 2 0 
1 18 1 17 10 2 8 6 0 6 
2 2 0 2 4 0 4 3 0 3 
3 1 0 1 1 0 1 1 0 1 
4 0 0 0 1 0 1 1 0 1 
5 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 1 0 1 
Total 56 33 23 28 12 16 14 2 12 
Table 1: Distribution of the samples identified as positive by the routine RT-PCR method (Cobas® SARS-CoV-2 assay) in the 
groups of 8, 16 and 32 and corresponding RT-dPCR detection of SARS-CoV-2 in the groups. 
Because sample pooling was performed systematically as samples came in the laboratory for routing 
RT-PCR testing, the groups contain variable numbers of RT-PCR positive samples (“RT-PCR+” samples). 
Given the positivity rate of RT-PCR at the time of the study, the majority of P8 extracts had no RT-PCR+ 
samples (35 out of 56) and 21 groups contained at least one RT-PCR+ sample, including 18 that had 
one single RT-PCR+ sample. 
For the largest group size of 32 samples, only 2 P32 groups had no RT-PCR+ samples. 12 P32 groups 
had at least one RT-PCR+ sample, including 6 with only one single RT-PCR+ sample. 
Detailed results for RT-dPCR in groups of 8 
The results for SARS-CoV-2 detection by RT-dPCR in groups of 8 samples, detailed in Tables 1 and 2, 
are in concordance with the reference individual RT-PCR testing for 52 groups (corresponding for 416 
samples), out of which 32 were RT-PCR negative groups and 20 groups contained at least one RT-PCR+ 
sample. 
For the remaining 4 groups with discording results, three RT-PCR negative groups tested positive by 
RT-dPCR (“RT-PCR-/dPCR+” discordances – group IDs: P8_20, P8_28 and P8_39) and one RT-PCR+ 
group was found negative by RT-dPCR (RT-PCR+/dPCR- discordance – group ID: P8_02). The Ct values 
for the sample associated with the RT-PCR+/dPCR- discordance was of 34 and 32.3 for the E gene and 
ORF1ab with the Cobas® SARS-CoV-2 assay, respectively. This sample is referred to as Sample 25659 
for later discussion. 
Complementary analysis of the discordances are depicted below. 
Of note, out of the 8 individual samples with Ct > 35 for the E gene, 6 ended up to be the only positive 
sample in a P8 extract and all the corresponding groups were detected positive by RT-dPCR. The 
highest detected Ct values for the E gene and ORF1ab were 38.7 and >40 (not detected), respectively. 
Confusion matrix for  
P8 extracts 
Expected negatives 
(RT-PCR) 
Expected positives 
(RT-PCR) Total 
Negatives in RT-dPCR 32 1 33 
Positives in RT-dPCR 3 20 23 
Total 35 21 56 
Table 2: Confusion matrix for P8 extracts 
Detailed results for RT-dPCR in groups of 16 
The results for SARS-CoV-2 detection by RT-dPCR in groups of 16 samples, detailed in Tables 1 and 3, 
are in concordance with individual RT-PCR testing for 25 groups (corresponding for 400 samples), out 
of which 11 are RT-PCR- groups and 14 are RT-PCR+ groups. Among the three groups with discording 
results, one presented a RT-PCR-/dPCR+ discordance (Group ID: P16_14) and two RT-PCR+/dPCR- 
discordances (Group IDs: P16_13 and P16_28). 
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Of note, out of the 8 individual samples with Ct > 35 for the E gene, 5 ended up to be the only positive 
sample in a P16 group. Two of these groups are responsible for the 2 RT-PCR+/dPCR- discordances. 
The E gene and OFR1ab Ct values for these 2 samples were of [36.7; >40 (not detected)] and [36.3; 
34.2], while the highest Ct values for a detected single positive sample were [38.3; >40 (not detected)]. 
Confusion matrix for  
P16 groups 
Expected negatives 
(RT-PCR) 
Expected positives 
(RT-PCR) 
Total 
Negatives in RT-dPCR 11 2 13 
Positives in RT-dPCR 1 14 15 
Total 12 16 28 
Table 3: Confusion matrix for P16 groups 
Detailed results for RT-dPCR in groups of 32 
The results for SARS-CoV-2 detection by RT-dPCR in groups of 32 are in concordance with individual 
RT-PCR testing for all 14 groups (corresponding for 448 samples) and are depicted in Tables 1 and 4. 
Out of the 8 individual samples with Ct >35 for the E gene, 3 ended up to be the only positive sample 
in a P32 group. All such 3 P32 groups tested positive by RT-dPCR. The highest detected Ct values for 
the E gene and ORF1ab is of [36.7; >40 (not detected)]. 
Confusion matrix for 
P32 groups 
Expected negatives 
(RT-PCR) 
Expected positives 
(RT-PCR) 
Total 
Negatives in RT-dPCR 2 0 2 
Positives in RT-dPCR 0 12 12 
Total 2 12 14 
Table 4: Confusion matrix for P32 groups 
Investigation of RT-PCR-/dPCR+ discordances 
As detailed above, three P8 extracts (P8_20, P8_28 & P8_39) and one P16 group (P16_14) tested 
positive by RT-dPCR while containing only RT-PCR negative samples. P16_14 originates from a 
combination of groups with opposite discordances: P8_27 (RT-PCR+/dPCR-) and P8_28 (RT-PCR-
/dPCR+) groups. 
To further investigate these RT-PCR-/dPCR+ discordances, confirmatory testing RT-dPCR was 
performed on all individual samples from corresponding groups. For each group, one sample tested 
positive by individual RT-dPCR, with measured concentrations of viral RNA ranging from 128 copies 
per reaction to 2 copies per reaction for the N gene, and from 106 to 1 copies for the ORF1ab gene. 
The three corresponding dPCR+ samples (sample IDs: 52042, 56075 and 60401) were retested on the 
Cobas® 6800 system and by confirmatory individual RT-qPCR using the Altona assay. All results are 
given in the Supplementary Materials. 
Two samples were found positive using the Altona assay with Ct values ranging between 28.4 and 33 
for the E and S genes. Among them, the sample presenting the highest viral load by RT-dPCR (Sample 
56075) was also found positive by the Cobas® confirmatory assay with a high Ct value of 36.7 for the E 
gene while the ORF gene was not detected. The remaining sample tested negative with both the 
confirmatory Cobas assay and the Altona assay. It had borderline levels of positive droplets in RT-dPCR 
(N=2; ORF1ab=1). 
Based on these results and for further sensitivity discussions, samples 52042 and 56075 that tested 
positive by both RT-dPCR and Altona RT-PCR are considered as true positive samples. Sample 60401 is 
considered an RT-dPCR false positive pending further analysis.  
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Investigation of the sample RT-PCR+/dPCR- 
One group of 8 (P8_02) was tested negative by RT-dPCR and contained one RT-PCR+ sample (Sample 
25659) with Ct values of 34 and 32.3 for the E gene and ORF1ab respectively. Sample 25659 was 
subsequently retested by RT-PCR on the Cobas protocol and was also re-extracted individually and 
retested by individual RT-dPCR.  
Sample_25659 was found to be borderline negative by RT-dPCR (N=2; ORF1ab=0) but Ct values of 37.3 
and 34.9 were found for E and ORF respectively in the second Cobas® assessment. 
Based on these results and for further sensitivity discussions, sample 25659 is considered as a true 
positive samples. 
Correlation between RT-dPCR measurements and Ct values 
A good correlation was observed between the number of positive droplets observed in RT-dPCR and 
the Ct values of the positive samples contained in the groups. See Supplementary Materials for more 
details. 
Discussion 
In this work, we assessed the sensitivity and specificity of group testing combined with digital PCR for 
SARS-CoV-2 detection. Three different group sizes were investigated using a commercially available 
digital PCR assay, the COVID-19 Multiplex Digital PCR Detection Kit (Stilla Technologies, 
France/Apexbio, China). This assay demonstrated a low LoB (at 2 and 0 positive droplets per PCR for N 
and ORF1ab genes, respectively) and low LoD (at 5 and 3 copies/PCR for N and ORF1ab genes, 
respectively). This LoD is lower than most estimation for WHO and other reference RT-PCR assays 
typically ranging between 5 to 500 copies/PCR (17,18).  
For our analysis, we proposed a protocol of group screening performed by RT-dPCR with secondary 
individual re-testing of positive groups as illustrated in Figure 3. 
 
Figure 3 : Graph of the suggested practical protocol for implementation of group testing by RT-dPCR. 
We assessed this protocol by assessing in real-life condition 448 consecutive samples grouped by 8, 16 
and 32 samples. 
 
We observed a better sensitivity than individual RT-PCR testing for groups of 8 samples. Indeed, a total 
of 23 groups of 8 samples tested positive and included 26 true positive samples. Only 25 samples were 
identified as positive using reference individual RT-PCR testing, corresponding to an +4% improvement 
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in sensitivity. Two among the three samples associated with RT-PCR-/dPCR+ discordances were 
confirmed as true positive by RT-PCR using a SARS-CoV-2 specific assay from Altona. The last one was 
not confirmed as positive by RT-PCR and is undergoing further investigations. One sample was 
associated to a RT-PCR+/dPCR- discrepant results and is also considered a true positive sample as 
confirmed by RT-PCR retesting. Further investigation by sequencing is underway on these 4 samples in 
an effort to rigorously assess the existence and nature of nucleic acids variations responsible for the 
discording results. 
 
Grouped testing by RT-dPCR has similar sensitivity to individual RT-PCR testing for a group size of 16 
samples. 15 groups of 16 samples tested by RT-dPCR positive and included a total of 25 true positive 
samples, of which 23 are RT-PCR positive samples and 2 are RT-PCR-/dPCR+ samples. However, 2 RT-
PCR+ groups tested negative with grouped RT-dPCR. This is likely explained by high Ct values of the 
single positive sample included in each of these 2 groups. 
 
Testing in the 14 groups of 32 samples by RT-dPCR has 100% concordance with the reference RT-PCR 
testing. Re-testing positive groups by RT-dPCR would have likely led to better sensitivity than RT-PCR.  
However, we are careful in drawing conclusions for groups of 32 given the limited data points in this 
case as only 14 groups, including only 2 RT-PCR negative groups. 
An alternative and even more cost-effective group testing protocol could be to perform the re-testing 
steps using RT-PCR with Cobas or Altona assays. In these protocols, the sensitivity becomes dependent 
on the RT-PCR kit used, leading to potential discrepancies with RT-dPCR as observed in our results for 
groups of 8 samples. However, our data suggest that performing the individual tests for groups of 8 
and 16 with a RT-PCR assay would still have a similar sensitivity. 
Overall, our data indicates that COVID-19 group testing combined with digital PCR for large group sizes 
of 8 and 16 samples, followed by individual re-testing of positive groups, has better or similar sensitivity 
than individual RT-PCR testing. Groups of 32 samples could also be considered, but our analysis needs 
to be confirmed in the future as, due to the epidemiological situation at the time, a low number of 
negative groups and groups containing a single positive sample were assessed. 
The gain in sensitivity of the proposed method is likely due to a combination of i) a concentration effect 
due to performing the pooling prior extraction and performing the extraction step from a large volume 
of 1 mL of pooled transport medium and ii) the intrinsic superior sensitivity of digital PCR compared to 
RT-PCR, as demonstrated previously for SARS-CoV-2 (14–16) and other viruses (12,19) detection. 
Below standard sensitivity is one of the main reasons why group testing has not been widely adopted 
for COVID-19 testing, whilst research groups have advocated for its implementation as a solution to 
the world-wide un-met demand for tests and reagent shortage(2-9). 
The current study suggests that the high sensitivity of group testing could be achieved using by digital 
PCR instead of RT-PCR in the first group screening step. It makes the approach viable for large-scale, 
low cost patient screening with minimum reagent consumption. For a test positivity rate of 1%, our 
group testing protocol would save 79%, 80% and 69% of reagents compared to individual testing, for 
group sizes of 8, 16 and 32 samples. Group size does not significantly impact cost or reagent 
consumption for group sizes above 8 samples and test positivity rates below 1%. Consequently, the 
choice of group size (8, 16 or 32) is mostly a balance of sensitivity and test capacity. Our results indicate 
that group testing by digital PCR and a group size of 16 would increase testing capabilities by more 
than 10-fold while having a sensitivity comparable to the current standard of individual testing by RT-
PCR. 
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Group testing can be used in various context where testing is not currently put in place due to testing 
capacity or with strong economics constraints and where SARS-CoV-2 prevalence is low. In countries 
where the pandemic is not yet under control or could re-emerge, enhancing testing capacity is 
essential to winning the battle against COVID-19. In countries where the first wave is fading, the fight 
against COVID-19 goes through a combination between a test / trace / isolate strategy and social 
distancing. Increasing the range of people tested amongst contacts with positive cases, but also 
periodic testing of population in frequent contact with others (e.g. nurses, transportation workers, 
clerks, etc…) as well as in fragile populations such as nursing homes can be part of a strategy against 
COVID-19 while allowing a relaxation of social distancing measures at the same time. Group testing 
can help in all of these situations.  
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Supplementary Materials 
 
S1 – Data format for RT-dPCR as obtained with the Naica System 
 
Figure S1.1: Fluorescence results as displayed in the Crystal Miner software showing 1D dot-plots of a positive (P8_42) and a 
negative (P8_44) pool of 8 samples in the FAM (A), HEX (B) and Cy5 (C) channels. The horizontal line marks the threshold above 
which droplets (represented as dots) are considered positive for the amplification of N, ORF1ab and for the endogenous 
internal control respectively. The thresholds are set by manufacturer at 20 000 RFUs, 15 000 RFUs and 15 000 RFUs for the 
FAM, HEX and Cy5 channels. (D) 3D dot-plots of P8_42: if the concentration of either target is high enough, co-encapsulation 
of several targets can occur in a droplet leading to the apparition of clusters for double positive droplets (cyan, yellow and 
purple) and triple positive droplets (light grey). Triple negative droplets, containing no target, are shown in the dark grey 
cluster.  
 
Figure S1.2: Image of the droplet crystal obtained using the Naica System on grouped extracts P8_22, including a zoom on a 
sub-region of the crystal. Droplet color code: dark grey = negative for all targets ; bleu : positive for N gene only ; green : 
positive for ORF1ab only; red : positive for IC only; cyan : positive for N and ORF1ab genes; magenta: positive for N gene and 
IC; yellow: positive for ORF1ab gene and IC; white / mixed: positive for all. The droplet crystal contains 25 820 analyzable 
droplets, out of which 1 057, 883 and 21 121 were positive for the N, ORF1ab and IC respectively.  
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S2 – Result table for LoB & LoD calculations 
Sample 
ID 
Number of 
droplets 
Pos. droplets 
(N+ORF1ab) 
Pos. droplets  
(N) 
Pos. droplets 
 (ORF1ab) 
IC 
(cp/µL) 
Group 1 19460 0 0 0 31430 
Group 2 20641 0 0 0 10985 
Group 3 21449 0 0 0 4054 
Group 4 20983 0 0 0 15143 
Group 5 19881 1 1 0 7401 
Group 6 20609 0 0 0 8783 
Group 7 19044 0 0 0 6249 
Group 8 20787 0 0 0 8759 
Group 9 21470 0 0 0 10271 
Group 10 18952 0 0 0 17578 
Group 11 23424 0 0 0 8222 
Group 12 22748 0 0 0 9875 
Group 13 23747 0 0 0 10275 
Group 14 24886 0 0 0 4266 
Group 15 24079 0 0 0 10264 
Group 16 24718 0 0 0 13219 
Group 17 24228 0 0 0 10186 
Group 18 23742 0 0 0 8431 
Group 19 23880 0 0 0 7628 
Group 20 23613 0 0 0 3111 
Group 21 25723 0 0 0 8987 
Group 22 25522 0 0 0 7411 
Group 23 24781 0 0 0 6894 
Group 24 7074 0 0 0 5884 
Group 25 27003 0 0 0 8911 
Group 26 27138 0 0 0 5552 
Group 27 24425 0 0 0 7886 
Group 28 27017 0 0 0 7484 
Group 29 26722 0 0 0 9963 
Group 30 26088 0 0 0 2492 
Group 31 26747 0 0 0 5703 
Group 32 26728 0 0 0 5825 
Table S2: Detection results in number of positive droplets for N, ORF1ab, N+ORF1ab and IC by RT-dPCR in 32 groups of 8 pre-
epidemic samples. 
The pre-epidemic groups were used as negative controls for SARS-CoV-2 detection. Only one out of 32 (group 5) 
had one positive droplet for the N target out of 19881 droplets analyzed. The LOB at 95% confidence level for 
this RT-dPCR assay was estimated automatically by the Gene-Pi online statistical tool (https://www.gene-
pi.com/statistical-tools/loblod/), considering a droplet volume of 0.548 nL as specified by the manufacturer. The 
LOD at 95% confidence level is computed from the experimental LOB. The LOB for the N and ORF1ab targets are 
found to be of 2 and 0 droplets respectively. The LODs are found to be of 0.46 copies/µL and 0.22 copies/µL, or 
equivalently of 7 and 3 copies per PCR reaction.  
Using a joint analysis, a LOB analysis can be performed for the combination of the N and ORF1ab targets. In the 
case, the sum of the positives for the N and OFR1ab target is used as the measure and the LOB for the sum is 2 
positive droplets. Consequently, in this study, a RT-dPCR result is considered as positive when the sum of positive 
droplets in the N and ORF1ab targets is of 3 droplets or more (strictly greater than 2). 
For details on calculation models, see: 
- https://www.gene-pi.com/wp-content/uploads/2018/03/Memo_LOB_calculation_method.pdf 
- https://www.gene-pi.com/wp-content/uploads/2019/11/GenePi_Memo_LOD_calculation_method-
1.pdf 
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S3 - Full results of pooled testing by RT-dPCR 
 
Sample_ID Ct_E Ct_ORF P8_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status P16_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status P16_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status
25652 21.2 20.9 P8_01 25340 25340 25128 15556 +/+ P16_01 25262 25196 22657 9080 +/+ P32_01 17348 16047 11332 9237 +/+
25653 38.01 0
 + 6 COBAS negative samples
25659 34.02 32.26 P8_02 25685 0 0 3642 +/-
+ 7 COBAS negative samples
8 COBAS negative samples P8_03 22995 1 0 5530 -/- P16_02 24508 0 0 10026 -/-
8 COBAS negative samples P8_04 26245 0 0 14896 -/-
27241 34 32.1 P8_05 26634 63 42 24859 +/+ P16_03 26718 980 350 15988 +/+ P32_02 4298 3890 3693 17412 +/+
+ 7 COBAS negative samples
27304 28.8 28.12 P8_06 27184 1767 650 8160 +/+
+ 7 COBAS negative samples
27316 27.71 27.1 P8_07 25752 3597 2667 13527 +/+ P16_04 26735 26497 26315 19941 +/+
+ 7 COBAS negative samples
27342 26.27 25.24 P8_08 26060 26059 26056 28478 +/+
+ 7 COBAS negative samples
30923 38.27 ND P8_09 25655 4 1 16784 +/+ P16_05 26446 4 1 18236 +/+ P32_03 21285 83 54 19589 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_10 25511 0 0 19934 -/-
8 COBAS negative samples P8_11 22083 0 0 17689 -/- P16_06 27274 224 125 21805 +/+
25736 34.5 32 P8_12 22503 418 256 29721 +/+
+ 7 COBAS negative samples
31173 38.73 ND P8_13 22408 3 2 13871 +/+ P16_07 23420 23420 23418 13459 +/+ P32_04 24222 24222 24221 14252 +/+
+ 7 COBAS negative samples
31271 18.71 17.81 P8_14 22982 22982 22974 14204 +/+
31278 36.52 34.83
31417 25.04 24.61
+ 5 COBAS negative samples
8 COBAS negative samples P8_15 22883 0 0 17210 -/- P16_08 21923 17166 14218 14676 +/+
31397 21.6 21.16 P8_16 24406 23431 21878 12568 +/+
31415 25.04 24.61
+ 6 COBAS negative samples
8 COBAS negative samples P8_17 25825 0 0 13476 -/- P16_09 24573 739 554 13055 +/+ P32_05 23569 319 202 12648 +/+
51318 28.35 27.89 P8_18 25304 1543 1189 15304 +/+
+ 7 COBAS negative samples
51958 35.15 32.25 P8_19 25088 40 39 16078 +/+ P16_10 26314 32 25 16918 +/+
+ 7 COBAS negative samples
52042 ND ND P8_20 25083 5 2 14024 -/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_21 24808 0 2 18935 -/- P16_11 24624 468 360 12282 +/+ P32_06 26550 305 212 13244 +/+
52408 28.81 28.22 P8_22 25820 1057 883 7399 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_23 23991 0 0 12420 -/- P16_12 25837 0 0 14885 -/-
8 COBAS negative samples P8_24 25510 0 0 16601 -/-
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Table S3: Results for A) individual reference RT-PCR testing; B) grouped testing by RT-dPCR for P8 extracts; C) grouped testing by RT-dPCR for P16 groups; and D) grouped testing by RT-dPCR for 
P32 groups. Highlighted in light green: results are in concordance (-/- or +/+). Highlighted in light orange: COBAS+/dPCR- discordance. Highlighted in light red: COBAS-/dPCR+ discordance.  ND= 
“Not detected”. 
Sample_ID Ct_E Ct_ORF P8_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status P16_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status P16_##
# of 
droplets
Pos droplets 
N
Pos droplets 
ORF
IC [C] 
(cp/µL)
COBAS/dPCR 
status
8 COBAS negative samples P8_25 25585 1 0 13405 -/- P16_13 25257 0 0 15031 +/- P32_07 25105 7 2 13330 +/+
27309 36.65 ND P8_26 25498 5 1 18210 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_27 25770 0 0 14721 -/- P16_14 25364 13 5 13146 -/+
56075 ND ND P8_28 25667 32 19 16170 -/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_29 25568 0 0 11813 -/- P16_15 27217 0 0 12192 -/- P32_08 26284 0 0 11980 -/-
8 COBAS negative samples P8_30 25757 0 0 12565 -/-
8 COBAS negative samples P8_31 25476 0 0 8230 -/- P16_16 27198 0 0 12741 -/-
8 COBAS negative samples P8_32 25324 0 0 17214 -/-
8 COBAS negative samples P8_33 25765 1 0 17060 -/- P16_17 26670 0 0 17539 -/- P32_09 26986 4628 3336 13335 +/+
8 COBAS negative samples P8_34 25803 0 0 17915 -/-
59120 24.1 23.28 P8_35 26095 14584 11406 9821 +/+ P16_18 25884 8381 6405 11333 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_36 25774 0 0 13463 -/-
8 COBAS negative samples P8_37 24635 1 0 10338 -/- P16_19 26555 0 0 14937 -/- P32_10 25842 230 184 12290 +/+
8 COBAS negative samples P8_38 24082 1 0 17996 -/-
60401 ND ND P8_39 26374 1 3 15263 -/+ P16_20 27345 506 415 11245 +/+
+ 7 COBAS negative samples
60611 28.14 27.86 P8_40 26259 979 757 7136 +/+
+ 7 COBAS negative samples
74465 16.5 16.3 P8_41 26883 26883 26883 8581 +/+ P16_21 24825 24825 24825 9690 +/+ P32_11 26391 26391 26391 9388 +/+
+ 7 COBAS negative samples
75547 31.3 29.4 P8_42 27389 2045 1905 11346 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_43 26105 0 0 5791 -/- P16_22 26078 0 0 9354 -/-
8 COBAS negative samples P8_44 25839 0 0 14504 -/-
8 COBAS negative samples P8_45 27194 0 1 12374 -/- P16_23 25239 0 0 17469 -/- P32_12 26536 0 0 18153 -/-
8 COBAS negative samples P8_46 26285 0 0 22379 -/-
8 COBAS negative samples P8_47 25420 0 0 24184 -/- P16_24 26470 0 0 19399 -/-
8 COBAS negative samples P8_48 26010 0 0 14457 -/-
8 COBAS negative samples P8_49 24858 0 0 12808 -/- P16_25 25065 4 3 13301 +/+ P32_13 26706 2 6 12266 +/+
79484 35.73 34.45 P8_50 25900 7 7 13425 +/+
+ 7 COBAS negative samples
8 COBAS negative samples P8_51 24696 0 0 16954 -/- P16_26 25356 0 0 11840 -/-
8 COBAS negative samples P8_52 25416 0 0 4837 -/-
8 COBAS negative samples P8_53 25625 0 0 12554 -/- P16_27 22665 0 0 9484 -/- P32_14 26044 2 1 6664 +/+
8 COBAS negative samples P8_54 23544 0 0 6078 -/-
83938 36.3 34.2 P8_55 22501 5 3 2607 +/+ P16_28 20171 2 0 5581 +/-
+ 7 COBAS negative samples
8 COBAS negative samples P8_56 23211 0 0 7245 -/-
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S4 – Detailed results of confirmatory testing for COBAS-/dPCR+ discordances 
Sample ID 
COBAS 
reference 
P8 extract 
number 
dPCR+/ 
dPCR- 
N 
cp / rnx  
ORF1ab 
cp / rnx 
IC 
cp / rnx 
Altona 
E gene 
Altona 
S gene 
COBAS 
N 
COBAS 
OFR 
51996 COBAS- 20 dPCR- 1 0 7 502   NT   NT   NT   NT  
52019 COBAS- 20 dPCR- 0 0 25 944   NT   NT   NT   NT  
52031 COBAS- 20 dPCR- 0 0 68 983   NT   NT   NT   NT  
52035 COBAS- 20 dPCR- 0 0 28 215   NT   NT   NT   NT  
52042 COBAS- 20 dPCR+ 16 19 a89 747  33  31.9 ND ND 
52047 COBAS- 20 dPCR- 0 0 122 825   NT   NT   NT   NT  
52060 COBAS- 20 dPCR- 0 0 17 237   NT   NT   NT   NT  
52062 COBAS- 20 dPCR- 0 0 105 711   NT   NT   NT   NT  
56075 COBAS- 28 dPCR+ 128 106 69 268  29  28.4 36.7 ND 
56077 COBAS- 28 dPCR- 0 0 34 656   NT  NT  NT  NT 
56083 COBAS- 28 dPCR- 0 0 71 410   NT  NT  NT  NT 
56191 COBAS- 28 dPCR- 0 0 22 471   NT  NT  NT  NT 
56211 COBAS- 28 dPCR- 0 0 21 185   NT  NT  NT  NT 
56275 COBAS- 28 dPCR- 0 0 22 771   NT  NT  NT  NT 
56303 COBAS- 28 dPCR- 0 0 56 797   NT  NT  NT  NT 
56307 COBAS- 28 dPCR- 0 0 59 159   NT  NT  NT  NT 
60241 COBAS- 39 dPCR- 0 0 46 988   NT  NT  NT  NT 
60281 COBAS- 39 dPCR- 1 0 73 581   NT  NT  NT  NT 
60310 COBAS- 39 dPCR- 0 0 11 420   NT  NT  NT  NT 
60334 COBAS- 39 dPCR- 0 0 32 663   NT  NT  NT  NT 
60345 COBAS- 39 dPCR- 0 0 81 004   NT  NT  NT  NT 
60362 COBAS- 39 dPCR- 0 0 36 943   NT  NT  NT  NT 
60389 COBAS- 39 dPCR- 0 0 825   NT  NT  NT  NT 
60401 COBAS- 39 dPCR+ 2 1 43 651   ND  ND ND ND 
Table S4: Results of the individual reassessment by both RT-dPCR and RT-PCR (Altona and Cobas®) for the samples from the 
3 “COBAS-/dPCR+” discordant groups. NT = “Not tested”. ND= “Not detected”. 
S5 - Absence of discordance in groups of 32 
In this study, we did not observe any discordance for test results in groups of 32 when compared to 
the reference individual RT-PCR results. In particular and surprisingly, there were no qPCR+/dPCR- 
discordances although we would suspect an increased occurrence of such discordances as group size 
increases from the dilution effect of group testing. 
Interestingly, the 2 samples that were associated with the 2 qPCR+/dPCR- discordances for groups of 
16 (with Ct values of [36.7; ND] and [36.3; 34.2] respectively) are both P32 groups that contained one 
single positive qPCR+ sample. Consequently, these two samples were successfully detected by RT-dPCR 
in groups of 32 (P32_07 & P32_14) but not detected in the groups of 16 (P16_13 & P16_28). 
In case of P32_07, the group of 32 is a combination of 2 P16 groups with opposite discordances: P16_13 
(qPCR+/dPCR-) and P16_14 (qPCR-/dPCR+). It is likely that the RNA templates from the P16_14 group 
are those that were detected in the P32_07 group. 
In the case of P32_14, the number of positive droplets observed in RT-dPCR is right above the threshold 
of 3 positive droplets (N=2; ORF1ab=1) while for the corresponding group of 16 (P16_28), the number 
of positive droplets is just below with 2 droplets (N=2; ORF1ab=0). In this case, statistical variations 
due to sampling error could explain the observation. 
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S6 – Correlation between RT-dPCR measurements and Ct values 
 
 
Figure S6.1: Plot of the number of positive droplets measured by RT-dPCR for the N gene target in the groups of 8, 16 and 32 
versus the predicted equivalent Ct value of the E gene of an RT-PCR measurement of the group using the Cobas® SARS-CoV-2 
assay. The predicted equivalent Ct value of a group is defined as an average of the Ct values of the positive samples included 
in the group, taking into account the logarithmic scale of the Ct value. 
 
 
Figure S6.2: Plot of the number of positive droplets measured by RT-dPCR for the ORF1ab gene target in the groups of 8, 16 
and 32 versus the predicted equivalent Ct value of the ORF gene of an RT-PCR measurement of the group using the Cobas® 
SARS-CoV-2 assay. The predicted equivalent Ct value of a group is defined as an average of the Ct values of the positive samples 
included in the group, taking into account the logarithmic scale of the Ct value. 
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